You are here: Industry Insights > Pancreatic cancer

News List

LYNPARZA (olaparib) get three new approvals in Japan expresspharma
December 29, 2020
Approvals in three types of cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials.
Triple combination of therapies shows promise in pancreatic cancer trial europeanpharmaceuticalreview
December 18, 2020
The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.
Rafael Pharmaceuticals Receives Fast Track Designation for CPI-613 americanpharmaceuticalreview
November 23, 2020
Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead compound, CPI-613® (devimistat), for the treatment of metastatic pancreatic cancer.
FDA Grants ODD for Esophageal, Gastroesophageal Junction, Pancreatic Cancer Treatment americanpharmaceuticalreview
October 21, 2020
Apexigen announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer.
Prestige Biopharma drug gets positive EMA opinion on Orphan Designation to treat pancreatic cancer expresspharma
October 19, 2020
Prestige BioPharma announced that the European Medicines Agency (EMA) Orphan Drug Commission (COMP) has granted a positive opinion for an Orphan Drug Designation (ODD) status to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the ...
Scientists at University of Sheffield discover new drug to treat pancreatic cancer expresspharma
September 18, 2020
Scientists at the University of Sheffield inform that they have invented a new drug which could improve life expectancy and quality for patients with hard-to-treat cancers, such as pancreatic cancer and relapsed breast cancer.
PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer pharmaceutical-business-review
September 08, 2020
PharmaCyte Biotech has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
Immunotherapies could target aggressive pancreatic cancer, research indicates pharmatimes
September 04, 2020
Researchers have discovered that an aggressive form of pancreatic cancer 'hijacks' the immune system's response and therefore is more likely to respond to treatment with immunotherapy, raising hopes for new targets in the fight against the disease.
EU nod for Lynparza in pancreatic cancer pharmatimes
July 09, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been approved in the EU for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
US FDA Grants Orphan Drug Designation (ODD) for Prestige BioPharma’s PBP1510 Anti-PAUF Monoclonal Antibody for the Treatment of Pancreatic Cancer B3C newswire
July 01, 2020
Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreat

Previous page 1 2 3 4 5 6 Next page